Plain-English translation of NCT07281924 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to treat advanced melanoma that has spread to the liver. The study combines a special procedure called Melphalan Percutaneous Hepatic Perfusion Therapy (HEPZATO KIT™) — which delivers chemotherapy directly into the liver where tumors are located — with two immunotherapy medications (, sold together as Opdualag) that help your immune system fight cancer. Researchers want to learn if this combination is safe and whether it can help shrink tumors.
Most melanoma treatments work throughout the entire body, which can cause side effects. This trial exists because doctors want to test whether sending chemotherapy directly to liver tumors, while also boosting the immune system's ability to fight cancer, might be more effective and easier to tolerate than standard treatments alone.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the chemotherapy delivery procedure (HEPZATO KIT™), which involves placing catheters into blood vessels to send medication directly to your liver tumors. You will also receive the two immunotherapy medications through standard infusions. You'll have regular visits for blood tests, imaging scans, and check-ins to monitor how you're responding and watch for any side effects. The study is currently recruiting about 15 participants and will carefully track how well the treatment works and how your body tolerates it.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States